BNP Hormone May Promote Blood Clot Formation, Study Finds

Key findings:

• BNP directly activates platelets through the natriuretic peptide receptor-A (NPRA).
• BNP–NPRA signaling increases platelet aggregation and thrombus formation.
• Blocking or removing NPRA prevents BNP-induced platelet activation.
• Targeting this pathway could support more specific antithrombotic treatments with fewer bleeding complications.
• For Latest Updates, Register for Cardiology CME Conferences & Online Courses

BNP Hormone and Its Role in Cardiovascular Blood Clotting

BNP hormone, commonly used to assess cardiac stress and heart failure, may directly contribute to blood clot formation, according to new research from Texas A&M University Health. Researchers found that elevated levels of B-type natriuretic peptide (BNP) activate blood platelets through a specific receptor pathway, potentially increasing the risk of thrombosis and serious cardiovascular complications.

The findings challenge the traditional understanding of BNP as primarily a diagnostic biomarker and identify a potential therapeutic target for preventing abnormal clot formation.

How Does the BNP Hormone Trigger Blood Clot Formation?

Led by Dr. Zhenyu Li, professor of pharmaceutical sciences at the Texas A&M University Irma Lerma Rangel College of Pharmacy, the research team investigated whether BNP contributes directly to cardiovascular disease progression.

BNP typically enters clinical evaluation as a biomarker of cardiac stress. Physicians measure its levels to help assess heart failure and other cardiovascular conditions. However, the researchers suspected that the hormone might also influence processes responsible for cardiovascular complications.

Their investigation revealed that BNP binds directly to NPRA, a specialized receptor on the surface of blood platelets. This interaction increases intracellular cyclic guanosine monophosphate (cGMP), activating signaling processes that promote platelet aggregation and thrombus growth.

The researchers observed accelerated clot formation in experimental models of vascular injury and pulmonary embolism when BNP levels increased.

Conversely, blocking or removing NPRA prevented BNP from activating platelets and reduced abnormal clot formation. The team also examined blood samples from patients with cardiac rhythm disorders and identified a correlation between circulating BNP levels and platelet activity.

These findings identify the BNP–NPRA signaling pathway as a potential contributor to thrombotic complications.

What Are the Clinical Implications of BNP–NPRA Signaling?

The discovery offers a possible explanation for the relationship between elevated BNP levels and increased cardiovascular complications, including heart attacks and pulmonary embolism.

Current antiplatelet medications suppress platelet activity throughout the body, potentially increasing the risk of internal bleeding. Targeting the BNP–NPRA pathway could offer a more selective approach by limiting BNP-driven platelet activation while preserving normal hemostasis.

However, the findings do not establish BNP-targeted treatment as a clinical intervention. Further investigation must determine the pathway’s contribution to thrombosis in different patient populations.

Future research will examine platelet-specific NPRA activity and identify small-molecule inhibitors that can disrupt the BNP–NPRA interaction. Dr. Li’s team is collaborating with researchers at Texas A&M to identify and evaluate potential inhibitors.

For Latest Updates, Register for Cardiology CME Conferences & Online Courses

If subsequent studies confirm these findings, BNP–NPRA signaling could provide a foundation for targeted therapies addressing thrombotic complications in patients with cardiovascular disease.

Source:

Texas A&M University